Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2024-01-29 00:00:00 ET · period of report 2024-01-25 · accession 0001415889-24-001896 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-29 | 2024-01-25 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $7.02 | +20.0K | 66.7K | +43% | +$140.4K |
| D | 2024-01-29 | 2024-01-25 | OLMA | Zojwalla Naseem | Chief MEDICAL Off | M - OptEx | $0.00 | -20.0K | 214.0K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-25 | M | A | 20,000 | $7.02 | 66,664 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-01-25 | M | D | 20,000 | $0.00 | 214,000 | D | $7.02 · — to 2032-01-31 | 20,000 Common Stock | (F1) 25% of the shares subject to the option vested on January 31, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |